Mizuho Markets Cayman LP Decreases Holdings in Illumina, Inc. (NASDAQ:ILMN)

Mizuho Markets Cayman LP reduced its position in Illumina, Inc. (NASDAQ:ILMN) by 23.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,168 shares of the life sciences company’s stock after selling 650 shares during the quarter. Illumina comprises approximately 1.2% of Mizuho Markets Cayman LP’s investment portfolio, making the stock its 17th biggest holding. Mizuho Markets Cayman LP’s holdings in Illumina were worth $283,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Janney Montgomery Scott LLC raised its stake in Illumina by 41.5% in the first quarter. Janney Montgomery Scott LLC now owns 3,070 shares of the life sciences company’s stock valued at $422,000 after buying an additional 900 shares during the last quarter. Empowered Funds LLC boosted its stake in Illumina by 26.9% in the 1st quarter. Empowered Funds LLC now owns 3,340 shares of the life sciences company’s stock worth $459,000 after purchasing an additional 708 shares in the last quarter. Sei Investments Co. boosted its stake in Illumina by 309.3% in the 1st quarter. Sei Investments Co. now owns 71,143 shares of the life sciences company’s stock worth $9,769,000 after purchasing an additional 53,761 shares in the last quarter. Bleakley Financial Group LLC purchased a new stake in Illumina during the 1st quarter worth approximately $207,000. Finally, Orion Portfolio Solutions LLC increased its stake in Illumina by 10.4% during the 1st quarter. Orion Portfolio Solutions LLC now owns 7,918 shares of the life sciences company’s stock valued at $1,087,000 after purchasing an additional 746 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $135.05 on Friday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The firm has a fifty day moving average of $139.66 and a 200 day moving average of $124.30. The firm has a market cap of $21.42 billion, a PE ratio of -13.56 and a beta of 1.13. Illumina, Inc. has a one year low of $92.69 and a one year high of $156.66.

Illumina (NASDAQ:ILMN) last released its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. During the same quarter in the previous year, the company earned $0.33 earnings per share. The company’s quarterly revenue was down 3.5% on a year-over-year basis. As a group, research analysts predict that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. TD Cowen boosted their price objective on shares of Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Barclays raised their price objective on Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Hsbc Global Res upgraded Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price on the stock in a research report on Thursday, October 17th. Robert W. Baird raised their price target on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Finally, Argus raised shares of Illumina from a “hold” rating to a “buy” rating and set a $150.00 price objective on the stock in a report on Wednesday, August 28th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $164.00.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.